文献速递淋巴瘤

BCL2与组蛋白去乙酰化酶抑制对皮肤T细胞淋巴瘤患者白血病细胞的协同作用

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
PubMed 文献 · Blood · 2017-10-02

研究从25例皮肤T细胞淋巴瘤(CTCL)患者外周血分离恶性细胞,体外比较BCL2抑制剂venetoclax单药及联用HDAC抑制剂vorinostat或romidepsin的敏感性,并与4株CTCL细胞系对照。多数患者样本对venetoclax敏感,BCL2表达水平与50%抑制浓度值负相关(r=-0.52;P=018)。venetoclax联合vorinostat的样本中93%、联合romidepsin的样本中73%显示协同效应,作者认为同时抑制BCL2与HDAC可能为晚期CTCL治疗提供协同作用。

要点

  • 25例CTCL患者外周血恶性细胞体外对venetoclax多数敏感,BCL2表达与50%抑制浓度值负相关(r=-0.52;P=018)。
  • venetoclax联合vorinostat的样本中93%显示协同效应。
  • venetoclax联合romidepsin的样本中73%显示协同效应。

核心结论

  • 数据强烈提示同时抑制BCL2与HDAC可能为晚期CTCL患者治疗提供协同作用。
  • 作者希望利用联合治疗并将反应与基因表达关联,实现更有效和个体化的CTCL治疗。

研究设计与样本

  • 从25例CTCL患者外周血分离恶性细胞,体外暴露于venetoclax、vorinostat、romidepsin单药及联合方案,并与4株CTCL细胞系(Hut78、Sez4、HH、MyLa)比较。

主要发现

  • 多数CTCL患者样本对venetoclax敏感,BCL2表达水平与50%抑制浓度值负相关(r=-0.52;P=018)。
  • venetoclax联合vorinostat的样本中93%显示协同效应。
  • venetoclax联合romidepsin的样本中73%显示协同效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The presence and degree of peripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available systemic therapies for CTCL may variably decrease tumor burden and improve quality of life, but offer limited effects on survival; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted. Mutational analyses of CTCL patient peripheral blood malignant cell samples suggested the antiapoptotic mediator B-cell lymphoma 2 (BCL2) as a potential therapeutic target. To test this, we developed a screening assay for evaluating the sensitivity of CTCL cells to targeted molecular agents, and compared a novel BCL2 inhibitor, venetoclax, alone and in combination with a histone deacetylase (HDAC) inhibitor, vorinostat or romidepsin. Peripheral blood CTCL malignant cells were isolated from 25 patients and exposed ex vivo to the 3 drugs alone and in combination, and comparisons were made to 4 CTCL cell lines (Hut78, Sez4, HH, MyLa). The majority of CTCL patient samples were sensitive to venetoclax, and BCL2 expression levels were negatively correlated (r = -0.52; P =018) to 50% inhibitory concentration values. Furthermore, this anti-BCL2 effect was markedly potentiated by concurrent HDAC inhibition with 93% of samples treated with venetoclax and vorinostat and 73% of samples treated with venetoclax and romidepsin showing synergistic effects. These data strongly suggest that concurrent BCL2 and HDAC inhibition may offer synergy in the treatment of patients with advanced CTCL. By using combination therapies and correlating response to gene expression in this way, we hope to achieve more effective and personalized treatments for CTCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cyrenne BM, Lewis JM, Weed JG, et al. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood. 2017. PMID: 28972015. doi:10.1182/blood-2017-06-792150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。